Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
Company to launch product after the expiry of semaglutide patent in India
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Subscribe To Our Newsletter & Stay Updated